Page last updated: 2024-09-05

deferasirox and Leukemia, Myeloid

deferasirox has been researched along with Leukemia, Myeloid in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hamamura, R; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T	1
Choi, CW; Kang, HN; Kang, MH; Kim, JL; Kim, JS; Yoo, YA	1
Al-awar, R; Alizadeh, S; Aman, A; Attisano, L; Bao, RY; Chau, A; Christova, T; Gronda, M; Hogge, DE; Hurren, R; Isaac, M; Jitkova, Y; Joseph, B; Kasper, J; Miller, BW; Perusini, S; Schimmer, AD; Song, S; Subramaniam, R; Weir, SJ; Wrana, JL	1

Trials

1 trial(s) available for deferasirox and Leukemia, Myeloid

Article	Year
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer research, 2011, Dec-15, Volume: 71, Issue:24 Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway	2011

Article

Year

Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.

Cancer research, 2011, Dec-15, Volume: 71, Issue:24

Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway

2011

Other Studies

2 other study(ies) available for deferasirox and Leukemia, Myeloid

Article	Year
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer science, 2009, Volume: 100, Issue:5 Topics: Animals; Apoptosis; Benzoates; Cell Line, Tumor; Deferasirox; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Protein Kinases; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays	2009
The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase. Acta haematologica, 2011, Volume: 126, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoates; Caspases; Cell Cycle; Cell Proliferation; Cell Survival; Deferasirox; Enzyme Activation; HL-60 Cells; Humans; Injections, Intraperitoneal; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proteolysis; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2011

Article

Year

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

Cancer science, 2009, Volume: 100, Issue:5

Topics: Animals; Apoptosis; Benzoates; Cell Line, Tumor; Deferasirox; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Protein Kinases; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays

2009

The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.

Acta haematologica, 2011, Volume: 126, Issue:4

Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoates; Caspases; Cell Cycle; Cell Proliferation; Cell Survival; Deferasirox; Enzyme Activation; HL-60 Cells; Humans; Injections, Intraperitoneal; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proteolysis; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2011